Swiss-based Santhera Pharmaceuticals has partnered with Cold Spring Harbor Laboratory (CSHL) to explore the use of lonodelestat (POL6014) as a potential treatment for acute respiratory distress syndrome (ARDS) caused by Covid-19.
CSHL researchers joined a new consortium of international non-clinical and clinical experts called ‘NETwork to target neutrophils in Covid-19’.
The consortium will analyse the role of neutrophils and neutrophil extracellular traps (NETs) in the Covid-19 pathology, while also investigating hNE and other targets for the treatment of the novel coronavirus infection.
NETs are macromolecular DNA structures and proteins that neutrophils can expel; hNE is generated by neutrophils during NETs formation.